Why Is Inovio Pharmaceuticals (INO) Stock Up +13.32% Today?
Key Takeaways
- Shares of INO climbed about 13.3% in midday trading Friday, extending a powerful two-session rally.
- The primary driver was follow-through from a Jefferies upgrade to Buy, tied to progress in the FDA review of lead candidate INO-3107.
- Supporting the move: a narrower-than-expected second-quarter loss, reduced operating expenses, and a cash runway extended into late first-quarter 2027.
- A technical break back above the $1.00 level and elevated volume amplified momentum, with short covering likely contributing.
- The move appeared stock-specific rather than part of a broad biotech rally, as sector trading was mixed.
- Traders are watching for FDA feedback, expected September label discussions, and the October 30 PDUFA decision.
Opening Summary
Inovio Pharmaceuticals, Inc. (INO) is a clinical-stage biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. In midday trading Friday, the stock was up roughly 13.3%, last changing hands at $1.02 versus Thursday's closing price of $0.9001. The advance extended a rally that began earlier this week after second-quarter results and a bullish analyst call centered on the company's lead drug candidate, INO-3107.
Analyst Upgrade Provides the Spark
The most direct catalyst behind the extended move is Thursday's upgrade from Jefferies, which lifted its rating on INO to Buy from Hold and raised its price target to $3.00 from $1.80. The firm cited a meeting with management and confidence that the FDA review of INO-3107 remains on track for its October 30, 2026 PDUFA target date. Jefferies noted that key review milestones had been completed without new issues, reinforcing the view that the company is moving toward a potentially transformative regulatory decision. Friday's follow-through suggests investors are continuing to reprice the stock after that more constructive stance.
FDA Review Progress and the INO-3107 Catalyst
Inovio has said the FDA completed its late-cycle review meeting and all scheduled pre-licensure inspections for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP. Management reiterated its confidence that the therapy qualifies for accelerated approval and expects to begin label negotiations in September. If approved, the company believes INO-3107 would receive seven years of orphan-drug market exclusivity and could become a new standard of care for RRP, where patients currently face repeated surgeries.
Q2 Earnings Beat and Cash Runway
The fundamental backdrop also improved. After Wednesday's close, INO reported a second-quarter net loss of $0.07 per share, far narrower than the $0.25 loss analysts had expected. Operating expenses declined 19% year over year to $18.6 million. The company ended June with $36.7 million in cash, cash equivalents, and short-term investments, and added about $18.3 million in net proceeds from a July public offering. Management said that funding should support operations into late first-quarter 2027, through a potential launch of INO-3107. Part of the improved bottom line reflected a non-cash warrant liability gain, but the cost discipline and extended runway still gave traders a clearer path to the PDUFA decision.
Technical Breakout Above $1.00
Friday's push also carried the stock back above the psychologically important $1.00 level for the first time since late July. With short interest at roughly 14.6% of shares outstanding, a round-number breakout in a small-cap biotech can accelerate momentum buying and force short sellers to cover. That technical dynamic, combined with heavy turnover, added fuel to an already bullish news cycle.
Market Context and Trading Activity
Trading volume was elevated relative to recent sessions, reflecting conviction rather than a passive drift higher. The move did not require a supportive tape: biotech trading was mixed Friday, and the advance in INO appeared largely stock-specific. The shares also benefited from positive Phase 3 results reported by partner ApolloBio for VGX-3100 in China, which provided independent validation of the company's DNA-medicine platform.
What Comes Next for INO
The next catalysts for INO are regulatory rather than financial. Investors are awaiting FDA feedback on the proposed confirmatory trial design, followed by label negotiations expected in September and the October 30 PDUFA decision for INO-3107. Risks remain: the FDA has not yet ruled on accelerated-approval eligibility, the company faces competition from an already-approved RRP therapy, and its cash runway extends only into late first-quarter 2027, meaning additional financing may eventually be needed. A binary FDA outcome is likely to keep volatility elevated in both directions.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to scan for approaches that are currently adapting best to shifting conditions. Explore the page to see which AI-driven strategies are standing out right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INO sees MACD Histogram just turned negative
INO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 37 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for INO moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 14 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INO as a result. In 66 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
INO moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INO crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for INO entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 183 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
INO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. INO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.701) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of synthetic vaccines and immune therapies for cancers and infectious diseases
Industry Biotechnology
Advertisement